Chemical Inhibitors to RAS Oncoproteins

Around one in every five human cancers have at least one form of RAS mutation (K-RAS, H-RAS, and N-RAS), making RAS the most frequently mutated gene family in human cancers.  Historically, these elusive RAS proteins have been called "undruggable", until a recent breakthrough from AmGen with the FDA’s approval of the anti-cancer drug sotorasib which targets a specific mutation, G12C, in the protein K-RAS.

Not surprisingly, there has been significant activity in this space recently and CAS provides a unique view into this landscape of emerging science in our latest white paper - "Chemical Inhibitors to RAS Oncoproteins: Current Landscape and Future Opportunities".

  Complete the form below to download the white paper.

Read the related CAS Blog - "Emerging trends in targeting "undruggable" RAS proteins for cancer treatment"